Post-earnings recap
Reported
Tue, May 9, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Amicus Therapeutics continues to face challenges, as reflected in the EPS miss. The stock reacted negatively, dropping 1.92%, likely due to the lack of revenue details and future guidance. Investors may be concerned about the company's financial health without clearer direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.39 | N/A | -2.77% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach regarding future performance. They emphasized the importance of their ongoing projects.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline despite the current losses.